Pharma company faces UCPMP probe over Rs 1.91 Crore spent on Doctors' Travel
In a first of its kind case under the Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024, the Apex Committee for Pharma Marketing Practices has issued a reprimand against AbbVie Healthcare India Private Ltd, a subsidiary of US-based AbbVie Inc., for unethical marketing practices. The company was allegedly found guilty of sponsoring international trips for nearly Rs 1.91 crore for 30 Healthcare Professionals (HCPs) under the pretense of professional development, contravening the UCPMP guidelines.
The case began with an anonymous complaint submitted to the Department of Pharmaceuticals (DoP) on May 21, 2024. The complaint, supported by internal company documents, alleged that AbbVie provided foreign travel and accommodation for 30 doctors attending the Aesthetics & Anti-Aging Medicine World Congress 2024 held in Monaco (February 1–3, 2024) and Paris (March 26–29, 2024). The alleged expenses totaled Rs 1.91 crore, covering flights and hotel stays.
For more information, click on the link below:
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.